Cancer Letters
Volume 291, Issue 1 , Pages 83-89 , 1 May 2010

Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model

  • Sang-Woo Lee

      Affiliations

    • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • These authors contributed equally to this work.
    • ,
  • You La Lee

      Affiliations

    • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • These authors contributed equally to this work.
    • ,
  • Yong Jin Lee

      Affiliations

    • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • ,
  • Seung-Yoon Park

      Affiliations

    • Department of Biochemistry, School of Medicine, Dongguk University, Kyungju 780-714, Republic of Korea
    • ,
  • In-San Kim

      Affiliations

    • Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • ,
  • Tae Hyun Choi

      Affiliations

    • Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 139-709, Republic of Korea
    • ,
  • Jeoung-Hee Ha

      Affiliations

    • Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • ,
  • Byeong-Cheol Ahn

      Affiliations

    • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • ,
  • Jaetae Lee

      Affiliations

    • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 53 420 5586; fax: +82 53 422 0864.

Received 31 August 2009 ,Revised 2 October 2009 ,Accepted 5 October 2009.

References 

  1. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 1990;82:297–300
  2. Ilsley DD, Lee SH, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases, alpha, delta and epsilon with very different potencies and have unique mechanisms of action. Biochemistry. 1995;34:2504–2510
  3. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274–5283
  4. Dilber MS, Abedi MR, Christensson B, Björkstrand B, Kidder GM, Naus CC, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 1997;57:1523–1528
  5. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliver. Rev. 2003;55:3–29
  6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Craig CM. Potent and specific genetic interference by double stranded RNA in caenorhabditis elegans. Nature. 1998;391:806–811
  7. Hannon GJ. RNA interference. Nature. 2002;418:244–251
  8. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell. 2001;107:309–321
  9. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. USA. 2000;97:2785–2790
  10. Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG and FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 2002;43:1072–1083
  11. Min JJ. Translational imaging with PET reporter gene approaches. Nucl. Med. Mol. Imag. 2006;40:279–292
  12. Park SY, Lee W, Lee J, Kim IS. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 2008;261:205–214
  13. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther. 2008;15:214–223
  14. Deng WP, Yang WK, Lai WF, Liu RS, Hwang JJ, Yang DM, et al. Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir. Eur. J. Nucl. Med. Mol. Imag. 2004;31:99–109
  15. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 2008;270:191–201
  16. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 1998;9:1083–1092
  17. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000;11:2389–2401
  18. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised,806 controlled study. Mol. Ther. 2004;10:967–972
  19. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res. 2005;11:7444–7453
  20. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61:3022–3026
  21. Boucher PD, Ostruszka LJ, Murphy PJ, Shewach DS. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 2002;9:1023–1030
  22. Boucher PD, Shewach DS. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol. Ther. 2005;12:1064–1071
  23. Hayashi K, Lee JB, Maitani Y, Toyooka N, Nemoto H, Hayashi T. The role of a HSV thymidine kinase stimulating substance, scopadulciol in improving the efficacy of cancer gene therapy. J. Gene Med. 2006;8:1056–1067
  24. Stefani AL, Barzon L, Castagliuolo I, Guido M, Pacenti M, Parolin C, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 2005;42:728–735
  25. Kagaya T, Nakamoto Y, Sakai Y, Tsuchiyama T, Yagita H, Mukaida N, et al. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 2006;13:357–366
  26. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur. J. Nucl. Med. Mol. Imag. 2005;32:836–842
  27. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 2000;12:450–458
  28. Wu H, Hait W, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515–1519
  29. Stierle V, Laigle A, Jolle B. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs. Biochem. Pharmacol. 2005;70:1424–1430
  30. Matsui Y, Kobayashi N, Nishikawa M, Takakura Y. Sequence-specific suppression of MDR1a/1b expression in mice via RNA interference. Pharm. Res. 2005;22:2091–2098
  31. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 2009;27:643–651
  32. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000;2:118–138
  33. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727–729
  34. Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martí-Climent J, Ruiz M, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128:1787–1795
  35. Wang HE, Yu HM, Liu RS, Lin M, Gelovani JG, Hwang JJ, et al. Molecular imaging with 123I-FIAU 18F-FUdR 18F-FET and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J. Nucl. Med. 2006;47:1161–1171
  36. Deng WP, Wu CC, Lee CC, Yang WK, Wang HE, Liu RS, et al. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J. Nucl. Med. 2006;47:877–884

PII: S0304-3835(09)00623-5

doi: 10.1016/j.canlet.2009.10.002

Cancer Letters
Volume 291, Issue 1 , Pages 83-89 , 1 May 2010

Article Tools

* Image Usage & Resolution